MRP2 inhibition is associated with improved efficacy of cisplatin sensitivity in hepatocellular carcinoma, and MRP2 knockout mice exhibit decreased excretion of the chemotherapeutics methotrexate and doxorubicin10,13. Here, ABCC2 is linked to hepatocellular carcinoma.